



Look out for AEIOU



DERMATOLOGY

Although rare, GPs need to be aware of Merkel cell carcinoma, the most malignant of all skin cancers.

DR PETER GORAYSKI AND ASSOCIATE PROFESSOR MICHAEL POULSEN

MERKEL cell carcinoma is the most malignant of all skin cancers, with more than one-third of patients dying of the disease. It is a rare malignancy, which predominantly affects sun-exposed areas in elderly patients.

Background

Merkel cell carcinoma of the skin is a rare neuroendocrine malignancy that exhibits an aggressive clinical course and possesses unique clinicopathological features.

Management is often complex and requires multidisciplinary input. Whereas the inherent dangers of melanoma are well known to the public, Merkel cell carcinoma remains unfamiliar, despite the fact that one-third of patients will die of the disease within five years of diagnosis.¹

Merkel cell carcinoma makes up a tiny proportion of all skin cancers and it is important for GPs to be aware of this condition so that appropriate management is initiated.

Incidence

The incidence in Queensland is 1.6 per 100,000, which is higher than in other states due to the high ultraviolet levels in Queensland.

Men (2.5 per 100,000) have a higher incidence than women (0.9 per 100,000), and rates peak at 20.7 per 100,000 for persons 80 years or older.

The overall incidence of Merkel cell carcinoma has been increasing at a rate of 2.6% per year from 1993 onwards.²

The reasons for this are speculative, but may in part be due to increased awareness of the diagnosis,



The acronym AEIOU — Asymptomatic, Expanding rapidly, Immunosuppression, Older than 50, and UV exposure — summarises the characteristic features of this disease.




patients living longer and the increased prevalence of immunosuppression in the community.

Aetiology

UV light has been implicated in the aetiology as there is an increased incidence related to the UVB index, and Merkel cell carcinoma occurs predominantly in sun-exposed areas of the skin.

A Merkel cell virus (MCV) has also been implicated by detecting the viral genome in 80% of Merkel cell carcinomas.³ In Aus-



tralia, the proportion with viral-related Merkel cell carcinoma is approximately 20% and the majority appear to be related to UV.

Clinical aspects

The lesions usually arise on areas of sun exposure, with 50% occurring on the head and neck region and 40% on the extremities.

Caucasian males predominate, and the median age is 70, with about 10% associated with immunosuppression.

Most lesions are asympto-

matic and characterised by a pattern of rapid growth. The lesions have a characteristic red or pink colour. The acronym AEIOU — Asymptomatic, Expanding rapidly, Immunosuppression, Older than 50, UV exposure — summarises the characteristic features of this disease.⁴

Despite its distinct clinical characteristics, the diagnosis is rarely made clinically, and only becomes apparent at biopsy.

The presence of these features should alert the GP to the potential diagnosis, and biopsy should proceed as soon as practicable. These clinical features are illustrated in the image.

Examination should be carried out with good light and magnification, looking for satellite lesions. The draining lymph nodes should be carefully evaluated as they are commonly involved.

There is commonly coex-

istence of other skin cancers or evidence of solar damage.

Patterns of spread

Examination of 5823 cases of Merkel cell carcinoma from the National Cancer Database showed that 66% presented with local disease, 27% presented with nodal disease and 7% with distant disease.⁵

Locally, this disease spreads via the dermal lymphatics and then to regional nodes. The presence of involved nodes increases the risk of distant metastases.

Investigations

The histological diagnosis is most commonly made by excision biopsy of the primary lesion.

For larger lesions, a punch biopsy should be performed prior to definitive treatment.

Merkel cell carcinoma
cont'd next page



from previous page is comprised of small blue cells, which may be confused with basal cell carcinoma, lymphoma, small cell carcinoma or neuroblastoma. Immunoperoxidase stains secure the diagnosis, and typically will be positive for neuroendocrine and cytokeratin markers. If there are palpable nodes, a fine needle aspirate should be done to confirm positivity.

All patients with Merkel cell carcinoma require clinical and radiological staging

so that treatment can be tailored to the extent of the disease. CT imaging of the relevant nodes should be undertaken, and the lungs and liver examined.

The use of PET imaging is being explored in this disease, but currently remains unfunded in Australia.

Stages I and II Merkel cell carcinomas are defined as disease that is localised to the skin at the primary site. Stage I is for primary lesions less than or equal to 2cm, and stage II is for primary lesions greater than 2cm.

Stage III is defined as disease that involves regional lymph nodes. Stage IV disease is found beyond regional lymph nodes.

Overview of treatment

Treatment is aimed at cure if the disease is confined to the primary site and nodes (stages I-III).

Factors that need to be taken into account are the patient's age and general condition, the site/stage of the disease, as well as preference for treatment.

The factors affecting treatment are summarised in the table opposite.

The mainstays of treatment are surgery and radiotherapy. Unlike melanoma of the skin, Merkel cell carcinoma is a very radio-sensitive disease and radiotherapy can be used as definitive treatment or as an adjuvant treatment following surgery.

The primary site, as well as the draining nodes, should be treated because of the high incidence of nodal spread.

Most Merkel cell carcinomas (stages I-II) are amenable to surgical excision and this allows the diagnosis to be made.

If there are satellite lesions, or if surgery will have an adverse impact on cosmesis or function, radiation may be used as the definitive treatment.

Surgical margins do not need to be wide if adjuvant radiotherapy is to be given, as local control appears to be equivalent for margin positive and margin negative disease with the appropriate use of radiotherapy.⁶

Adjuvant radiotherapy courses usually extend over a five-week period, and offer high levels of regional control.

For stage I Merkel cell carcinoma, the use of adjuvant nodal radiotherapy has been shown in a randomised trial to reduce the risk of regional relapse from 16.7% to 0%, and this has now become the standard of care in clinically node-negative patients.⁷

The side effects of radiotherapy will depend on the site to be treated. Patients will experience a skin reaction with dry or moist desquamation as well as fatigue.

Radiation mucositis, xerostomia and loss of taste may occur with radiotherapy in the head and neck site.

With the availability of three-dimensional planning and intensity-modulated radiation therapy, radiation oncologists are able to minimise dose to normal tissues and reduce the side effects of treatment.

Although early Merkel cell carcinoma may be managed with wide surgi-

FACTORS AFFECTING TREATMENT FOR MERKEL CELL CARCINOMA

Patient factors	Tumour factors	Treatment factors
<ul style="list-style-type: none"> • Age and general condition • Renal and marrow function • Immunosuppression • Condition of the skin • Adjacent critical normal tissues • Patient preference 	<ul style="list-style-type: none"> • T stage • N stage • Presence of distant disease • Site of the tumour • Molecular factors 	<ul style="list-style-type: none"> • Availability of radiotherapy • Adequacy of the excision margins • Previous treatment with radiation

cal excision alone in carefully selected patients, there is compelling evidence that the addition of radiotherapy improves loco-regional control and survival.⁸

Radiotherapy is not necessary for lesions less than 1cm in size, with no lymphovascular invasion, that have been widely excised with clear margins and a negative sentinel node biopsy, and not associated with any immunosuppression.

With the increasing use of sentinel node biopsy, which provides prognostic information, adjuvant radiotherapy may be avoided if the biopsy result is negative, accepting that the patient may progress in 20% of cases.⁹

However, all patients with a positive sentinel node biopsy result require nodal treatment with surgery or radiotherapy.

Like small cell lung cancer, Merkel cell carcinoma is a chemosensitive disease. Chemotherapy has been mainly used as a palliative treatment in patients with stage IV disease.

The use of adjuvant chemotherapy and chemo-

radiotherapy has been explored in high-risk Merkel cell carcinoma in an attempt to reduce the risk of distant spread and improve survival.¹⁰

However, at present, the routine use of chemotherapy is not recommended outside the context of a clinical trial.

New systemic options are being evaluated, which may impact management. Blockade of programmed death, an inhibitory receptor expressed by T-cells, can overcome immune resistance. This is being explored in patients with recurrent and metastatic Merkel cell

carcinoma and shows promise.^{11,12}

There are no randomised trials comparing the different treatment strategies, and a multitude of surgical and non-surgical approaches exist.

A multidisciplinary approach is favoured to help achieve good treatment outcomes while minimising the toxicities of treatment.¹³

Prognosis

The overall survival for Merkel cell carcinoma in Queensland in a population-based study was 41% at five years.²

This makes Merkel cell



carcinoma the most malignant of skin conditions. Results are better for patients younger than 70, for head and neck sites, and for earlier stage disease.

Implications for GPs

Although rare, GPs need to be aware of this very aggressive skin cancer, which needs urgent referral for ongoing specialist management.

Radiotherapy has been shown to increase survival and loco-regional control.●

Dr Gorayski is a consultant radiation oncologist at Mater Private Hospital Springfield, Queensland; School of Medicine, University of Queensland, Brisbane. Associate Professor Poulsen is a senior radiation oncologist, Radiation Oncology Mater Centre, Brisbane, Queensland; School of Medicine, University of Queensland, Brisbane.

Acknowledgements
We wish to acknowledge the support of Radiation

Oncology Centres and ICON Consolidated Holdings.

References

1. *International Journal of Radiation Oncology, Biology, Physics* 2010; 77:677-84.
2. *JAMA Dermatology* 2014; 150:864-72.
3. *Science* 2008; 319:1096-1100.
4. *Journal of the American Academy of Dermatology* 2008; 58:375-81.
5. *Journal of the American Academy of Dermatology* 2010; 63:751-61.
6. *International Journal of Radiation Oncology, Biology, Physics* 2013; 86:91-95.
7. *Annals of Oncology* 2012; 23:1074-80.
8. *Journal of Clinical Oncology* 2007; 25:1043-47.
9. *Australasian Journal of Dermatology* 2012; 53:26-31.
10. *Journal of Clinical Oncology* 2003; 21:4371-76.
11. *Current Treatment Options in Oncology* 2013; 14:249-63.
12. *New England Journal of Medicine* 2016; 374:2542-52.
13. *Journal of Clinical Oncology* 2015; 33:3338-45.

Think beyond statin monotherapy¹

Patients with primary hypercholesterolaemia not at LDL-C target on:

rosuvastatin Switch

RosuZet[®]
COMPOSITE PACK
(ezetimibe and rosuvastatin)

10mg + 5mg 10mg + 10mg 10mg + 20mg 10mg + 40mg

PBS Information: Authority required (STREAMLINED). Patient must be on maximally tolerated statin dose before switching to statin and ezetimibe combination therapy. Refer to PBS Schedule for full authority information.

Before prescribing, please review the Product Information. The Product Information can be accessed at www.msinfo.com.au/rosuzetpi

Minimum PI for RosuZet COMPOSITE PACK Indications: as adjunctive therapy to diet in patients with primary hypercholesterolaemia where use of a combination product is appropriate - in those patients not appropriately controlled with rosuvastatin or ezetimibe alone; or already treated with rosuvastatin and ezetimibe. Patients with homozygous familial hypercholesterolaemia. **Contraindications:** Any dose; hypersensitivity; myopathy secondary to other lipid lowering agents; pregnancy; lactation; active liver disease; unexplained persistent elevations of serum transaminases; tics; acid; fenofibrate (gall bladder disease only). 40 mg dose only; hypothyroidism; history of muscular toxicity with HMG-CoA reductase inhibitors/fibrates, or personal/family history of muscular disorders; alcohol abuse; situations which may increase rosuvastatin plasma levels (see PI); severe renal impairment; Asian patients; fibrates. **Precautions:** **Liver function:** monitor liver enzymes before treatment and periodically when clinically indicated; high alcohol use; history of liver disease; moderate-severe hepatic insufficiency (not recommended). **Myopathy/rhabdomyolysis:** interrupt therapy in sepsis, hypotension, major surgery, trauma, severe metabolic, endocrine and electrolyte disorders, or uncontrolled seizures; renal impairment; age >65 years; hypothyroidism; other lipid-lowering therapies such as niacin; gemfibrozil (avoid or do not exceed 10+10mg daily); other fibrates (not recommended) except fenofibrate; protease inhibitors; cyclosporin (do not exceed 10+5mg daily; monitor); situations which may increase rosuvastatin plasma levels (see PI). 10+40mg dose (monitor); anticoagulants (warfarin, coumarin derivatives: monitor INR); elevated HbA1c and fasting glucose levels; ketoconazole, spiroprolactone and cimetidine (endocrine effects); interstitial lung disease (discontinue); women of childbearing potential (ensure adequate contraception); children (not recommended); driving and operating machinery. **Pregnancy:** Category D. **Interactions:** antacids, bile acid binding sequestrants (dose several hours apart). Others - see above. **Adverse effects:** abdominal distension; abdominal pain; constipation; dry mouth; nausea; asthenia; fatigue; arthralgia; myalgia; allergic dermatitis; eczema; skin exfoliation; ALT increased. Others - see full PI. **Dosage:** one EZETROL tablet and one MSD ROSUVASTATIN tablet at the same time daily (any time of day). Do not chew or crush tablet. Starting dose 10+5mg or 10+10mg once daily, adjust after 4 weeks if required. Usual maximum dose 10+20mg daily; 10+40mg dose requires regular follow-up (consider specialist supervision and renal monitoring). No dosage adjustment for elderly, mild hepatic insufficiency, mild-moderate renal impairment. Severe renal impairment not on dialysis: start at 10+5mg daily and do not exceed 10+10mg. Asian patients: start at 10+5mg daily and do not exceed 10+20mg. Co-administrations: see above and full PI. Not recommended in children, moderate-severe liver insufficiency. **Overdosage:** symptomatic and supportive measures should be employed. Based on PI approved 7 August 2015. **References:** 1. RosuZet Composite Pack Approved Product Information, 7 August 2015.

Copyright © 2016 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, New Jersey, U.S.A. All rights reserved. Merck Sharp & Dohme (Australia) Pty Limited. Level 1 - Building A, 26 Talavera Road, Macquarie Park NSW 2113. CARD-1190058-0001. First issued July 2016. Bloe Agency MSD12677R_AD_A4

Before prescribing, please review the Product Information available at www.seqirus.com.au/PI.

MINIMUM PRODUCT INFORMATION: PALEXIA[®] SR (tapentadol hydrochloride) INDICATION: Moderate to severe chronic pain unresponsive to non-narcotic analgesia. **CONTRAINDICATIONS:** Known hypersensitivity to tapentadol or any component of Palexia SR; conditions in which mu-opioid receptor agonist activity is contraindicated e.g. significant respiratory depression and acute or severe bronchial asthma or hypercapnia; confirmed or suspected paralytic ileus; acute intoxication with alcohol; hypnotics, centrally acting analgesics or psychotropic drugs; patients who are receiving MAO inhibitors or who have taken them within the last 14 days. **PRECAUTIONS:** Monitor for signs of abuse and addiction; repeated administration may lead to tolerance; withdrawal symptoms could occur after abrupt discontinuation; not recommended in patients with increased intracranial pressure, impaired consciousness, or cornea and severe renal or severe hepatic impairment; caution in patients with impaired respiratory functions, patients with head injury, brain tumours, a history of seizures or any condition that increases risk of seizures, moderate hepatic impairment or biliary tract disease, including acute pancreatitis. Use in pregnancy (Category C). Should not be used during breastfeeding. Not recommended for children <18 years old. May impair ability to drive or operate machinery. **INTERACTIONS:** Care should be taken when combining with mixed opioid agonist/antagonists or partial mu-opioid agonists; additive CNS depression with concomitant administration of other mu-opioid receptor agonist analgesics, general anaesthetics, phenothiazines, other tranquilisers, sedatives, hypnotics or other CNS depressants (including alcohol and illicit drugs) - reduction of dose of one or both agents should be considered; contraindicated in patients who are receiving MAO inhibitors or who have taken them within the last 14 days; isolated case reports of serotonin syndrome when used in combination with serotonergic drugs (see full PI). **ADVERSE EFFECTS:** Very common (≥1/10): dizziness, somnolence, headache, nausea, constipation; Common (≥1/100 to <1/10): Decreased appetite, anxiety, depressed mood, sleep disorder, nervousness, restlessness, disturbance in attention, tremor, muscle contractions involuntary, flushing, dyspnoea, vomiting, diarrhoea, dyspepsia, pruritus, hyperhidrosis, rash, asthenia, fatigue, feeling of body temperature change, mucosal dryness, oedema. Postmarketing: suicidal ideation, angioedema, anaphylaxis and anaphylactic shock. **DOSE AND ADMINISTRATION:** To be taken orally twice daily, whole with sufficient liquid, approximately every twelve hours, with or without food. **Initiation of therapy in patients currently not taking opioid analgesics:** start with 50 mg Palexia SR twice daily. **Initiation of therapy in patients currently taking opioid analgesics:** nature, administration and mean daily dose of previous medication should be taken into account. **Titration and maintenance:** titrate individually to a level that provides adequate analgesia and minimises side effects under close supervision of prescribing physician; titration regimen in increments of 50 mg twice daily every 3 days shown to be appropriate in most patients in clinical trials. Total daily doses >500 mg not recommended. **Discontinuation of treatment:** taper dose gradually to prevent symptoms of withdrawal. **Renal impairment:** not recommended in severe renal impairment. **Hepatic impairment:** initiate at 50 mg once daily in moderate hepatic impairment; not recommended in severe hepatic impairment. Elderly patients more likely to have decreased renal and hepatic function - care in dose selection. Not recommended for use in children <18 years old. Based on approved Product Information dated 17 September 2015. **REFERENCES:** 1. Palexia SR Approved Product Information, 17 September 2015. PALEXIA[®] SR is a registered trademark of Grünenthal Pty Ltd. PALEXIA[®] SR is distributed by Seqirus (Australia) Pty Ltd under licence from Grünenthal Pty Ltd. Seqirus (Australia) Pty Ltd ABN 66 120 398 067, 63 Poplar Road Parkville, Victoria 3052. www.seqirus.com.au. Medical Information: 1800 642 865. Seqirus[™] is a trademark of Seqirus UK Limited or its affiliates. Date of preparation: December 2015. AUS/PAL/0515/00922, BIGP10632, Ward6.

CONFIDENCE IN PAIN RELIEF*

*PALEXIA[®] SR has proven efficacy and GI tolerability in patients with moderate to severe osteoarthritis, chronic low back pain, diabetic peripheral neuropathy and cancer pain¹



PALEXIA[®] SR
tapentadol sustained release

PBS Information: Restricted benefit. Chronic severe disabling pain not responding to non-narcotic analgesics. Authority required for increased maximum quantities and/or repeats. Refer to PBS schedule for full restricted benefit and authority information.